Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Sell
45
PRPH Quote, Financials, Valuation and Earnings
Last price:
$0.37
Seasonality move
:
5.38%
Day range:
$0.33 - $0.37
52-week range:
$0.22 - $5.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.12x
P/B ratio:
2.10x
Volume:
251.3K
Avg. volume:
2.4M
1-year change:
-92.55%
Market cap:
$15.4M
Revenue:
$6.8M
EPS (TTM):
-$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRPH
ProPhase Labs
|
$2.5M | -$0.18 | -32.58% | -48.57% | $13.80 |
|
APDN
Applied DNA Sciences
|
$1.2M | -$3.00 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
OCX
OncoCyte
|
$126.8K | -$0.25 | -27.97% | -77.88% | $4.42 |
|
VCYT
Veracyte
|
$111M | $0.20 | 14.14% | -93.75% | $42.20 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRPH
ProPhase Labs
|
$0.37 | $13.80 | $15.4M | -- | $0.00 | 0% | 1.12x |
|
APDN
Applied DNA Sciences
|
$0.85 | -- | $935K | -- | $0.00 | 0% | 0.05x |
|
FONR
Fonar
|
$12.02 | -- | $76.1M | 10.45x | $0.00 | 0% | 0.76x |
|
OCX
OncoCyte
|
$3.44 | $4.42 | $98.4M | -- | $0.00 | 0% | 23.89x |
|
VCYT
Veracyte
|
$32.23 | $42.20 | $2.5B | 107.43x | $0.00 | 0% | 5.62x |
|
XWEL
XWELL
|
$0.78 | -- | $4.1M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRPH
ProPhase Labs
|
31.06% | -3.205 | 37.21% | 1.12x |
|
APDN
Applied DNA Sciences
|
-- | 5.762 | -- | 4.28x |
|
FONR
Fonar
|
0.03% | 1.790 | 0.07% | 10.85x |
|
OCX
OncoCyte
|
-- | -0.940 | -- | 1.41x |
|
VCYT
Veracyte
|
-- | 3.539 | -- | 4.27x |
|
XWEL
XWELL
|
-- | -1.288 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
APDN
Applied DNA Sciences
|
$684.1K | -$3M | -113.07% | -113.07% | -247.7% | -$3.4M |
|
FONR
Fonar
|
$9.7M | $2.4M | 4.95% | 4.95% | 11.92% | $1.5M |
|
OCX
OncoCyte
|
$595K | -$5.4M | -581.11% | -581.11% | -2253.1% | -$5.6M |
|
VCYT
Veracyte
|
$78.8M | $6M | 2.14% | 2.14% | 2.9% | $20.4M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
ProPhase Labs vs. Competitors
-
Which has Higher Returns PRPH or APDN?
Applied DNA Sciences has a net margin of -209.38% compared to ProPhase Labs's net margin of -220.57%. ProPhase Labs's return on equity of -59.59% beat Applied DNA Sciences's return on equity of -113.07%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs-5.25% -$0.35 $55.3M APDNApplied DNA Sciences57.17% -$28.00 $12.5M -
What do Analysts Say About PRPH or APDN?
ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3640.85%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 176974.73%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs0 0 0 APDNApplied DNA Sciences0 1 0 -
Is PRPH or APDN More Risky?
ProPhase Labs has a beta of -0.562, which suggesting that the stock is 156.182% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.856, suggesting its less volatile than the S&P 500 by 14.433%.
-
Which is a Better Dividend Stock PRPH or APDN?
ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or APDN?
ProPhase Labs quarterly revenues are $3.1M, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. ProPhase Labs's net income of -$6.6M is lower than Applied DNA Sciences's net income of -$2.6M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.12x versus 0.05x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs1.12x -- $3.1M -$6.6M APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M
-
Which has Higher Returns PRPH or FONR?
Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 7.87%. ProPhase Labs's return on equity of -59.59% beat Fonar's return on equity of 4.95%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs-5.25% -$0.35 $55.3M FONRFonar39.03% $0.29 $159M -
What do Analysts Say About PRPH or FONR?
ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3640.85%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs0 0 0 FONRFonar0 0 0 -
Is PRPH or FONR More Risky?
ProPhase Labs has a beta of -0.562, which suggesting that the stock is 156.182% less volatile than S&P 500. In comparison Fonar has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.736%.
-
Which is a Better Dividend Stock PRPH or FONR?
ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or FONR?
ProPhase Labs quarterly revenues are $3.1M, which are smaller than Fonar quarterly revenues of $25M. ProPhase Labs's net income of -$6.6M is lower than Fonar's net income of $2M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 10.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.12x versus 0.76x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs1.12x -- $3.1M -$6.6M FONRFonar0.76x 10.45x $25M $2M
-
Which has Higher Returns PRPH or OCX?
OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -2255.11%. ProPhase Labs's return on equity of -59.59% beat OncoCyte's return on equity of -581.11%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs-5.25% -$0.35 $55.3M OCXOncoCyte40.04% -$1.93 -$12.3M -
What do Analysts Say About PRPH or OCX?
ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3640.85%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 28.39%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs0 0 0 OCXOncoCyte1 2 0 -
Is PRPH or OCX More Risky?
ProPhase Labs has a beta of -0.562, which suggesting that the stock is 156.182% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.709%.
-
Which is a Better Dividend Stock PRPH or OCX?
ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or OCX?
ProPhase Labs quarterly revenues are $3.1M, which are larger than OncoCyte quarterly revenues of $1.5M. ProPhase Labs's net income of -$6.6M is higher than OncoCyte's net income of -$33.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.12x versus 23.89x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs1.12x -- $3.1M -$6.6M OCXOncoCyte23.89x -- $1.5M -$33.5M
-
Which has Higher Returns PRPH or VCYT?
Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 4.31%. ProPhase Labs's return on equity of -59.59% beat Veracyte's return on equity of 2.14%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs-5.25% -$0.35 $55.3M VCYTVeracyte66.39% $0.06 $1.2B -
What do Analysts Say About PRPH or VCYT?
ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3640.85%. On the other hand Veracyte has an analysts' consensus of $42.20 which suggests that it could grow by 30.93%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs0 0 0 VCYTVeracyte7 2 1 -
Is PRPH or VCYT More Risky?
ProPhase Labs has a beta of -0.562, which suggesting that the stock is 156.182% less volatile than S&P 500. In comparison Veracyte has a beta of 2.032, suggesting its more volatile than the S&P 500 by 103.174%.
-
Which is a Better Dividend Stock PRPH or VCYT?
ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or VCYT?
ProPhase Labs quarterly revenues are $3.1M, which are smaller than Veracyte quarterly revenues of $118.6M. ProPhase Labs's net income of -$6.6M is lower than Veracyte's net income of $5.1M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is 107.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.12x versus 5.62x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs1.12x -- $3.1M -$6.6M VCYTVeracyte5.62x 107.43x $118.6M $5.1M
-
Which has Higher Returns PRPH or XWEL?
XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -56.4%. ProPhase Labs's return on equity of -59.59% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs-5.25% -$0.35 $55.3M XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About PRPH or XWEL?
ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3640.85%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 800.79%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs0 0 0 XWELXWELL0 0 0 -
Is PRPH or XWEL More Risky?
ProPhase Labs has a beta of -0.562, which suggesting that the stock is 156.182% less volatile than S&P 500. In comparison XWELL has a beta of 2.106, suggesting its more volatile than the S&P 500 by 110.579%.
-
Which is a Better Dividend Stock PRPH or XWEL?
ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or XWEL?
ProPhase Labs quarterly revenues are $3.1M, which are smaller than XWELL quarterly revenues of $8.4M. ProPhase Labs's net income of -$6.6M is lower than XWELL's net income of -$4.8M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.12x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs1.12x -- $3.1M -$6.6M XWELXWELL0.11x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
